Acorda wins big over thwarted patent challenger Bass as PTO upholds Ampyra's IP

The U.S. Patent and Trademark Office has upheld the IP protection on Acorda's Amprya.

Acorda Therapeutics can chalk up another win over patent challenger Kyle Bass and his Coalition for Affordable Drugs.

Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board upheld all four patents on multiple sclerosis med Ampyra, thwarting Bass’ attempt to get the Ardsley, New York-based drugmaker’s IP tossed out.

It’s a “great victory” for Acorda and “certainly the drug industry” as it handles challenges from Hayman Capital Management founder Bass and others who follow his lead, Paul Hastings LLP’s Naveen Modi, who co-led Acorda’s legal effort, said in an interview. Bass has been using the inter partes review system, initially set up to weed out low-quality patents involved in litigation, to attack the IP shields of drugmakers he’s shorted, profiting from the process when his activities spook investors and send shares south.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

While Acorda was the first company Bass took to task, he’s followed up with a series of challenges to pharmas including Celgene and Biogen, and industry watchers have been closely following the Acorda case for clues of how Bass’ strategy might play out down the line.

From here on out, hedge funds “will have to really think about ... what they want to put forward in a challenge like these,” Modi said, noting that “I would hope this discourages entities like Hayman Capital from filing challenges like the ones that were filed here.”

This was Bass’ second go-around with Acorda on the IPR front. Before the PTAB decided to initiate reviews on the set of four patents, it declined to do so with a previous set.

Unfortunately for Acorda, though, it’s not completely out of the woods. It’s also fighting three ANDA challengers to uphold its patents in court, where it’ll need another win to protect its Ampyra franchise, Leerink Partners’ Paul Matteis wrote in a note to clients. All told, he expects to see generics descend on the med in 2020.

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.